Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
Yanzhen Zhang, Huaigang Chen, Lang Hong, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 25

Showing 25 citing articles:

From Atherosclerotic Plaque to Myocardial Infarction—The Leading Cause of Coronary Artery Occlusion
Ewelina Młynarska, Witold Czarnik, Piotr Fularski, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7295-7295
Open Access | Times Cited: 13
A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies
Vasudeva Reddy Netala, Sireesh Kumar Teertam, Huizhen Li, et al.
Cells (2024) Vol. 13, Iss. 17, pp. 1471-1471
Open Access | Times Cited: 13
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins
Maurizio Capuozzo, Alessandro Ottaiano, Claudia Cinque, et al.
Hipertensión y Riesgo Vascular (2025)
Closed Access | Times Cited: 1
Lipids dysregulation in diseases: core concepts, targets and treatment strategies
Tikam Chand Dakal, Feng Xiao, Chandra Kanta Bhusal, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach
Piotr Fularski, Witold Czarnik, Bartłomiej Dąbek, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5212-5212
Open Access | Times Cited: 7
Dendritic cells immunotargeted therapy for atherosclerosis
Zhaohui Li, Yanyan Yang, Jinbao Zong, et al.
Acta Pharmaceutica Sinica B (2025) Vol. 15, Iss. 2, pp. 792-808
Open Access
Current Clinical Trials for Treating Elevated Lipoprotein(a)
Chris De Los Reyes, Rishi Rikhi, Sean Doherty, et al.
Current Cardiovascular Risk Reports (2025) Vol. 19, Iss. 1
Closed Access
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Daniele Tramontano, Simone Bini, Carlo Maiorca, et al.
Drugs (2025)
Open Access
Deep learning and natural products for mitigating drug-induced liver injury in HCV, PFIC, PBC, liver fibrosis, neoplasia, and atherosclerosis
S. Sharma, Jayaprakash Chinnappan
Deleted Journal (2025) Vol. 7, Iss. 5
Open Access
Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups
YuBin He, Xin Guan, YaYun Zhang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-9
Closed Access | Times Cited: 2
Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction
Jakub Michał Zimodro, Aleksandra Gąsecka, Piotr Arski, et al.
Archives of Medical Science (2024) Vol. 20, Iss. 3, pp. 1043-1047
Open Access | Times Cited: 2
Metabolic Syndrome and Pharmacological Interventions in Clinical Development
Eugen Javor, David Šarčević, Arnes Rešić
Diabetology (2024) Vol. 5, Iss. 3, pp. 300-320
Open Access | Times Cited: 2
miR‐148a‐3p mitigation of coronary artery disease through PCSK9/NF‐κB inhibition of vascular endothelial cell injury
Jiong Tang, Menghuai Ma, Fan Liu, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 11
Closed Access | Times Cited: 2
Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
Suyi Zhang, Lei Sun, Xinyu Xu, et al.
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Novel diamine-scaffold based N-acetylgalactosamine (GalNAc)–siRNA conjugate: synthesis and in vivo activities
Qiang Li, Mingxin Dong, Pu Chen
RSC Advances (2024) Vol. 14, Iss. 25, pp. 17461-17466
Open Access | Times Cited: 1
Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for RIBOTACs and siRNA Therapy
Nicolas Hulscher, Peter A. McCullough, Diane Marotta
(2024)
Open Access | Times Cited: 1
Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review
S Knežević, Francesca Filippi-Arriaga, Andrej Belančić, et al.
Diabetology (2024) Vol. 5, Iss. 4, pp. 406-429
Open Access | Times Cited: 1
Developing a Ready-to-Use Lipid Nanoparticle Technology for Nucleic Acid Delivery Based on Deep Eutectic Solvents
Yuning Wei, Weiwen Kong, Zirong Dong, et al.
Nano Letters (2024)
Closed Access | Times Cited: 1
Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS
Xuezhong Shi, Ying Qiao, Yongli Yang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-6
Closed Access | Times Cited: 1
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database
Xuyang Cai, Shaopeng Peng, Shangzhen Mu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-6
Closed Access
A Comparative Analysis of Low-Density Lipoprotein Cholesterol (LDL-C)-Lowering Activities of Bempedoic Acid, Inclisiran, and PCSK9 Inhibitors: A Systematic Review
Yazhini Rajendran, Madhumita Nandhakumar, Madhavi Eerike, et al.
Cureus (2024)
Open Access
Inclisiran in India: A Game-changer for Dyslipidemia Management
A.N. Patnaik
Indian Journal of Clinical Cardiology (2024) Vol. 5, Iss. 4, pp. 323-324
Open Access
A Novel Pot-Economy Approach to the Synthesis of Triantennary GalNAc-Oligonucleotide
Artem Evgenievich Gusev, Vladimir Ivanov, Nikolai Andreevich Dmitriev, et al.
Molecules (2024) Vol. 29, Iss. 24, pp. 5959-5959
Open Access
Strategic deactivation of mRNA COVID‐19 vaccines: New applications for siRNA therapy and RIBOTACs
Nicolas Hulscher, Peter A. McCullough, Diane Marotta
The Journal of Gene Medicine (2024) Vol. 26, Iss. 9
Open Access
What are the benefits and drawbacks of statins in carotid artery disease? A perspective review
S.A.M. Said, Alan Dardik, Cassius Iyad Ochoa Chaar
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 11, pp. 763-777
Open Access
Page 1

Scroll to top